Isatuximab addition shows benefits in relapsed, refractory multiple myeloma

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 15 / Springer Healthcare

Isatuximab addition shows benefits in relapsed, refractory multiple myeloma

University Hospital Hôtel-Dieu, Nantes, France

Haematology EHA-2020

Description

Philippe Moreau tells us why the phase 3 IKEMA trial supports the addition of the anti-CD38 agent isatuximab to carfilzomib plus dexamethasone as a potential new standard of care for relapsed or refractory multiple myeloma.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.